Publication: Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review
Issued Date
2021-03-01
Resource Type
ISSN
10958584
00222828
00222828
Other identifier(s)
2-s2.0-85098087554
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Molecular and Cellular Cardiology. Vol.152, (2021), 105-117
Suggested Citation
Petra Mamic, Thanat Chaikijurajai, W. H.Wilson Tang Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review. Journal of Molecular and Cellular Cardiology. Vol.152, (2021), 105-117. doi:10.1016/j.yjmcc.2020.12.001 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/76274
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review
Author(s)
Abstract
Gut microbiome (GMB) has been increasingly recognized as a contributor to development and progression of heart failure (HF), immune-mediated subtypes of cardiomyopathy (myocarditis and anthracycline-induced cardiotoxicity), response to certain cardiovascular drugs, and HF-related comorbidities, such as chronic kidney disease, cardiorenal syndrome, insulin resistance, malnutrition, and cardiac cachexia. Gut microbiome is also responsible for the “gut hypothesis” of HF, which explains the adverse effects of gut barrier dysfunction and translocation of GMB on the progression of HF. Furthermore, accumulating evidence has suggested that gut microbial metabolites, including short chain fatty acids, trimethylamine N-oxide (TMAO), amino acid metabolites, and bile acids, are mechanistically linked to pathogenesis of HF, and could, therefore, serve as potential therapeutic targets for HF. Even though there are a variety of proposed therapeutic approaches, such as dietary modifications, prebiotics, probiotics, TMAO synthesis inhibitors, and fecal microbial transplant, targeting GMB in HF is still in its infancy and, indeed, requires further preclinical and clinical evidence. In this review, we aim to highlight the role gut microbiome plays in HF pathophysiology and its potential as a novel therapeutic target in HF.